Telesis Bio Inc., a leader in DNA and mRNA synthesis solutions, has announced a licensing agreement with Regeneron Pharmaceuticals, Inc. to implement the Gibson SOLA™ platform at Regeneron's R&D core facilities. This innovative platform is designed to enhance on-site DNA and gene synthesis, significantly reducing the timeline for therapeutic research and drug development. The Gibson SOLA platform enables fully-enzymatic, overnight synthesis of high-fidelity DNA and mRNA, allowing for faster iteration and improved data security by eliminating the need for external service providers. This agreement marks an industry trend towards internalizing synthetic biology capabilities to accelerate drug discovery and development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telesis Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528071860) on May 28, 2025, and is solely responsible for the information contained therein.